{
    "clinical_study": {
        "@rank": "129442", 
        "acronym": "NCATS", 
        "arm_group": [
            {
                "arm_group_label": "PF-03463275 Active Dose#1", 
                "arm_group_type": "Experimental", 
                "description": "Active Dose between 10 mg"
            }, 
            {
                "arm_group_label": "PF-03463275 Active Dose #2", 
                "arm_group_type": "Experimental", 
                "description": "Active dose between 20 mg"
            }, 
            {
                "arm_group_label": "PF-03463275 Active Dose #3", 
                "arm_group_type": "Experimental", 
                "description": "Active dose between 40mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo- no active dose of PF-03463275."
            }
        ], 
        "brief_summary": {
            "textblock": "This study involves an interlinked design to determine the dose associated with optimal\n      activity and occupancy of the Glyt1I  PF-03463275 in healthy subjects and schizophrenia\n      subjects and to test this dose in combination with cognitive remediation in the treatment of\n      cognitive impairments of Schizophrenia."
        }, 
        "brief_title": "Translational Neuroscience Optimization of GlyT1 Inhibitor", 
        "condition": "Cognitive Impairments Associated With Schizophrenia", 
        "condition_browse": {
            "mesh_term": [
                "Schizophrenia", 
                "Cognition Disorders"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1) Males or females 21 to 55 years of age (inclusive).\n\n          -  3) Able to provide written informed consent.\n\n          -  4) Only CYP2D6 extensive metabolizers.\n\n        Exclusion Criteria:\n\n          -  1) No ongoing acute medical issues\n\n          -  2) Clinically significant ECG abnormality\n\n          -  3) Blood donation within eight weeks of the start of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911676", 
            "org_study_id": "1303011716"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PF-03463275 Active Dose#1", 
                    "PF-03463275 Active Dose #2", 
                    "PF-03463275 Active Dose #3"
                ], 
                "intervention_name": "PF-03463275", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 28, 2014", 
        "location": {
            "contact": {
                "email": "michelle.carbuto@yale.edu", 
                "last_name": "Michelle Carbuto, BA", 
                "phone": "203-376-3850"
            }, 
            "facility": {
                "address": {
                    "city": "New Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06519"
                }, 
                "name": "Connecticut Mental Health Center"
            }, 
            "investigator": {
                "last_name": "Deepak C D'Souza, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Translational Neuroscience Optimization of GlyT1 Inhibitor", 
        "other_outcome": {
            "description": "To test the efficacy of PF03463275 on Cognitive Test Performance in subjects with Schizophrenia", 
            "measure": "Efficacy of PF03463275 on cognitive measures in Schizophrenic subjects.", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline in cognitive measures at 5 weeks"
        }, 
        "overall_contact": {
            "email": "michelle.carbuto@yale.edu", 
            "last_name": "Michelle K Carbuto, BA", 
            "phone": "(203) 376-3850"
        }, 
        "overall_official": {
            "affiliation": "Yale University", 
            "last_name": "Deepak C D'Souza, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To  examine the receptor occupancy associated with PF-03463275.", 
            "measure": "Receptor Occupancy after administration of PF-03463275  using PET.", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline in Receptor Occupancy at 6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911676"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Yale University", 
            "investigator_full_name": "Deepak C. D'Souza", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "To test whether PF-03463275 alters Pre-Frontal Cortex function during a working memory task in a dose-related manner, as measured with fMRI.", 
            "measure": "Alteration in  Pre-Frontal Cortex function with PF-03463275", 
            "safety_issue": "No", 
            "time_frame": "Change from Baseline in Pre-frontal Cortex Function at 6 weeks"
        }, 
        "source": "Yale University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yale University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}